DSIP

DSIP, the short name for Delta Sleep-Inducing Peptide, is built from nine linked amino acids; researchers first isolated it and worked out its structure from rabbit brain tissue in 1977. Researchers originally studied it for its apparent link to deep sleep, and later work looked at broader effects on stress hormones and pain signaling. The evidence includes both animal studies and a handful of small human trials, though how the peptide works is still not fully settled.

What it is

DSIP is a short natural peptide made of nine amino acids, isolated and chemically characterized in 1977 from rabbit brain tissue while researchers investigated what triggers deep, slow-wave sleep. Chemists classify it as a nonapeptide. Its name reflects that original discovery, though later research broadened well beyond sleep alone.

Researchers have proposed that DSIP acts on more than one brain signaling system in parallel, including the systems that respond to GABA and NMDA, two of the brain's major chemical messengers, and the body's own natural opioid system. It has also been studied for a role in regulating the hypothalamic-pituitary-adrenal axis, the hormone pathway that governs the body's stress response. Exactly how these separate actions combine, and which one matters most, remains an open question in the literature.

How it is studied

DSIP research includes both animal experiments, mostly in rats, and a small number of human studies, some using a double-blind, placebo-controlled design. Human work has looked at sleep quality over a handful of nights rather than long-term use. Because DSIP is reported to break down quickly in the body, most studies have focused on short observation windows measured in minutes to hours after it is given.

What studies report

Researchers first isolated DSIP from rabbit brain tissue in 1977 and confirmed, under masked testing conditions, that the synthesized nine-amino acid peptide specifically produced deep, slow-wave brain-wave patterns that other similar peptides did not. [schoenenberger-1977]
In a double-blind study of sixteen people with long-term insomnia, DSIP given into a vein before three nights of sleep modestly improved objective sleep quality, including higher sleep efficiency and a shorter time to fall asleep, compared with a placebo solution; the researchers concluded the effect was weak and unlikely to offer major therapeutic benefit. [bes-1992]
In eleven healthy men, a single into-the-vein amount of DSIP lowered a stress-hormone signal called ACTH in blood for at least three hours afterward, without changing cortisol levels, evidence that DSIP affects the body's stress-hormone system beyond sleep. [bjartell-1989]
In rats given a stroke-like brain injury, eight days of DSIP given through the nose sped up recovery of motor coordination on a balance test compared with untreated rats, though the amount of damaged brain tissue was not significantly different between the two groups. [tukhovskaya-2021]

What is not known

How consistently any sleep benefit holds up outside small, short trials is not resolved by the available literature; the largest double-blind human sleep study found the effect too weak to be of clear therapeutic value. How the peptide's several proposed brain-signaling effects, including its action on stress hormones and on recovery after stroke in rats, relate to one another and to its original sleep effect is also not settled. Long-term safety data in people is limited, since human studies have generally lasted only a handful of nights.

Regulatory status

No national medicines regulator anywhere, the United States Food and Drug Administration included, has approved DSIP for use in people. It is absent from the World Anti-Doping Agency's roster of banned substances.